Search

Your search keyword '"Rudin, Charles M"' showing total 1,870 results

Search Constraints

Start Over You searched for: Author "Rudin, Charles M" Remove constraint Author: "Rudin, Charles M"
1,870 results on '"Rudin, Charles M"'

Search Results

1. Automated real-world data integration improves cancer outcome prediction

3. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

6. CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation

8. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

9. Reply to P. de Boissieu et al

10. Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer

12. TGF-β and RAS jointly unmask primed enhancers to drive metastasis

14. Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer

15. Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies

16. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

17. ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1

20. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade

21. Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation

22. Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies

24. Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma

25. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

27. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance

28. Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

30. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

33. Genomic mapping of metastatic organotropism in lung adenocarcinoma

34. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

35. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade

36. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer

37. cfDNA methylome profiling for detection and subtyping of small cell lung cancers

39. Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis

40. Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations

41. BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

43. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC

44. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC

45. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

46. Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers

47. Inferring gene expression from cell-free DNA fragmentation profiles

48. ONECUT2 is a driver of neuroendocrine prostate cancer.

50. Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts

Catalog

Books, media, physical & digital resources